Venetoclax: a new weapon to treat high-risk CLL
Mené sur 107 patients atteints d'une leucémie lymphocytaire chronique réfractaire ou récidivante avec délétion du chrosomome 17p, cet essai multicentrique international de phase II évalue l'efficacité, du point de vue du pourcentage de patients avec une réponse globale, et la toxicité du vénétoclax
Ibrutinib and idelalisib, the first of a new class of agents that inhibit the microenvironment-activated kinases that chronic lymphocytic leukaemia cells are addicted to, revolutionised the treatment of this disease. Despite accumulating favourable outcome data reported for kinase inhibitors and the unprecedented advancement in the management of chronic lymphocytic leukaemia with these agents, TP53 genetic defects still affect the duration of remission in relapsed and refractory patients, and their management is an incompletely met medical need.
The Lancet Oncology 2016